ArticleAmerican journal of translational research2025
Effect of Traditional Chinese Medicine Jie Yu Xiao Yin on thyroid antibodies and inflammatory biomarkers in Hashimoto's thyroiditis patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study assesses the efficacy of Jie Yu Xiao Yin (JYXY), a Traditional Chinese Medicine (TCM) formulation, on Hashimoto's Thyroiditis (HT).
methodsNinety HT patients (2020-2022) were randomized to JYXY + levothyroxine (n = 45) or levothyroxine alone (n = 45) for 12 weeks. JYXY (300 mL/day) and levothyroxine (12.5-25 µg/day) were provided. Thyroid hormones (thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3)), antibodies (thyroid peroxidase (TPOAb), thyroglobulin (TGAb)), interleukin (IL 6, 10, 12, 17), transforming growth factor-beta (TGF-β), and TCM scores were measured at baseline and in weeks 4, 8, and 12. The final study included 86 patients (44 treatment and 42 control).
resultsBaseline parameters were comparable (P > 0.05). At week 12, the treatment group showed greater reductions in TSH (3.06 ± 0.59 vs. 4.89 ± 0.71; P < 0.001), TPOAb (165.37 ± 8.55 vs. 199.28 ± 13.81 IU/mL; P < 0.001), and TGAb (159.77 ± 9.37 vs. 178.26 ± 13.04 IU/mL; P < 0.001). Pro-inflammatory cytokines decreased significantly in the JYXY group: IL-6 (16.02 ± 6.34 vs. 19.84 ± 5.21), IL-17 (21.07 ± 8.95 vs. 30.45 ± 10.12), and TGF-β (18.91 ± 6.12 vs. 22.34 ± 5.67) (all P < 0.001). IL-10 and IL-12 remained unchanged (P > 0.05). TCM scores improved markedly (3.70 ± 0.90 vs. 7.42 ± 4.38; P < 0.001), with higher clinical efficacy (87.63% vs. 69.05%; P < 0.001).
conclusionsJYXY coupled with levothyroxine improves thyroid function, decreases autoantibodies and pro-inflammatory cytokines (IL-6, IL-17, TGF-β), and alleviates symptoms in HT patients, outperforming levothyroxine alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.